Advancing Psoriasis Care Through Selective TYK2 Inhibition

April Armstrong, MD, MPH, reframes psoriasis as a systemic inflammatory disease and highlights a shift toward earlier systemic treatment, with emerging oral therapies like TYK2 inhibitors offering improved efficacy and safety.

April Armstrong, MD, MPH, highlights envudeucitinib as a next-generation oral TYK2 inhibitor that delivers biologic-level efficacy and strong safety, expanding treatment options for patients with moderate to severe psoriasis.

April Armstrong, MD, MPH, discusses the role of itch as a key driver of psoriasis burden and shows how next-generation oral TYK2 inhibitors like envudeucitinib provide rapid symptom relief and meaningful improvements in quality of life.